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Abstract
Background: Pancreatic cancer is the fourth leading cause of cancer related deaths in the United States with a five-year
survival rate of 6%. It is characterized by extremely aggressive tumor growth rate and high incidence of metastasis. One of
the most common and profound biochemical phenotypes of animal and human cancer cells is their ability to metabolize
glucose at high rates, even under aerobic conditions. However, the contribution of metabolic interrelationships between
tumor cells and cells of the surrounding microenvironment to the progression of cancer is not well understood. We
evaluated differential expression of metabolic genes and, hence, metabolic pathways in primary tumor and metastases of
patients with pancreatic adenocarcinoma.
Methods and Findings: We analyzed the metabolic gene (those involved in glycolysis, tri-carboxylic acid pathway, pentose-
phosphate pathway and fatty acid metabolism) expression profiles of primary and metastatic lesions from pancreatic cancer
patients by gene expression arrays. We observed two principal results: genes that were upregulated in primary and most of
the metastatic lesions; and genes that were upregulated only in specific metastatic lesions in a site-specific manner.
Immunohistochemical (IHC) analyses of several metabolic gene products confirmed the gene expression patterns at the
protein level. The IHC analyses also revealed differential tumor and stromal expression patterns of metabolic enzymes that
were correlated with the metastasis sites.
Conclusions: Here, we present the first comprehensive studies that establish differential metabolic status of tumor and
stromal components and elevation of aerobic glycolysis gene expression in pancreatic cancer.
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Introduction
Cancer cells demonstrate significant alterations in energy
metabolism in order to fuel uncontrolled cell proliferation and
facilitate invasive properties [1]. Under aerobic conditions, normal
cells utilize glucose to generate energy through glycolysis in the
cytosol and Krebs cycle in the mitochondria [1]. However, as
observed first by Otto Warburg, cancer cells reprogram glucose
metabolism by facilitating the flux of glucose through glycolysis,
while limiting the flux of glucose through Krebs cycle in
mitochondria [2]. These alterations in the flux of glucose under
aerobic conditions have been termed aerobic glycolysis [3]. Such
reprogramming in energy metabolism significantly diminishes
ATP production but facilitates rapid synthesis of metabolites,
which generate building blocks to support rapid cell growth [4].
Decreased energy production during aerobic glycolysis is balanced
by rapid glucose uptake that is accomplished in part by
upregulation of glucose transporters such as GLUT1 [5]. Like
most cancers, pancreatic ductal adenocarcinoma (PDAC) cells also
demonstrate increased uptake of glucose [6]. This property of
pancreatic cancer cells is exploited for noninvasive imaging of
pancreatic tumors by utilizing a radiolabeled analog of glucose
(18F-fluorodeoxyglucose, FDG) to visualize glucose uptake using
positron emission tomography (PET) [7,8].
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linked with clinical outcome in cancer patients [9]. Previous
studies have linked expression alterations and polymorphisms in
genes regulating glucose metabolism to clinical outcome in
pancreatic cancer. A significant correlation has been identified
between GLUT1 expression and pancreatic cancer prognosis [10].
Furthermore, higher expression of GLUT1 correlates with
advanced stages of pancreatic intraepithelial neoplasias (PanIN)
and non invasive intraductal papillary mucinous neoplasms
(IPMN) [10]. Also, alterations in glucose metabolism have been
linked with cell survival in pancreatic cancer [11]. In a large study,
Dong et al. found that polymorphisms or mutations in glucose
metabolic genes in patients with localized tumor, and in patients
with advanced diseases were significant independent predictors for
overall survival [12]. Thus, alterations in glycolytic enzyme
expression and activities are critical to cancer prognosis.
Activating oncogene mutations and loss-of-function tumor
suppressor mutations have been shown to further facilitate aerobic
glycolysis. The oncogene Myc directly regulates expression of
several glycolytic genes, and the oncogenes Ras and Src indirectly
regulate the expression of glycolytic genes by regulating the
expression of hypoxia inducible factor (HIF)-1, a key metabolic
modulator [13]. The tumor suppressor p53 regulates expression of
TIGAR (TP53-induced glycolysis and apoptosis regulator), which
lowers the levels of fructose-2,6-bisphosphate in cells, resulting in
an inhibition of glycolysis [14]. As p53 mutations are highly
prevalent in pancreatic cancer, one effect is to relieve this
glycolytic block and facilitate cancer progression. It has been
hypothesized that most genetic alterations in tumors facilitate
metabolic reprogramming, which, in turn, facilitates tumor growth
and metastasis.
Although several studies have addressed changes in the
expression levels of individual genes, the overall picture of
metabolic reprogramming in pancreatic cancer remains far from
clear [7,10,15]. In this study extensive expression analyses were
evaluated to determine the expression levels of all the glucose
metabolic genes in pancreatic tumors from primary and metastatic
lesions. Several candidate metabolic genes, whose expression were
significantly elevated in the primary tumors or in the tumors at
individual metastatic sites in comparison to the normal tissues,
were further evaluated for expression in tissue microarrays. The
results clearly indicate elevation in the expression of several
glycolytic genes in primary and metastatic tumors, suggesting a
role of aerobic glycolysis in pancreatic cancer progression.
Furthermore, we found that these genes were significantly
overexpressed in tumor cells as compared to the stromal cells,
suggesting that aerobic glycolysis may be more frequent in the
tumor cell component of the pancreatic cancer.
Methods
Patients
PDAC samples from 35 patients with metastatic PDAC from
the University of Nebraska Medical Center Rapid Autopsy
Pancreatic Program (RAP) were evaluated for differentially
expressed genes (at mRNA or protein levels). Human pancreatic
tumors, metastatic lesions, and uninvolved specimens harvested by
rapid autopsy from preconsented decedents previously diagnosed
with pancreatic ductal carcinoma, were obtained from the
University of Nebraska Medical Center’s Tissue Bank through
the Rapid Autopsy Pancreatic program. Written consent was
obtained from patients prior to death. The Rapid Autopsy sample
collection was performed as per the University of Nebraska
Medical Center Institutional Review Board (UNMC-IRB) ap-
proval (approval # 091-01-FB).
RNA Isolation and Microarray Hybridization
Frozen sections from each tissue sample (Table 1) were
homogenized in TRIZOL reagent (Invitrogen Life Technologies,
Carlsbad, CA USA). Total RNA was extracted using a standard
chloroform protocol followed by purification with the Qiagen
RNeasy Mini Kit (QIAGEN Inc, Valencia, CA USA). RNA
Table 1. Tissue sections from pancreatic cancer patient autopsies that were utilized for gene expression arrays.
Subjects by tissue
Tissue
Subject Primary Metastasis
Pancreas Fat Liver Lung Lymph node Muscle Bowel Spleen Vessel Total
21 0 000 0 0 0 0 1
31 5 114 0 1 0 0 13
41 0 301 2 0 0 0 7
51 0 401 0 0 0 0 6
60 2 100 1 1 0 0 5
71 0 121 2 0 0 0 7
81 0 100 0 0 0 0 2
93 0 221 0 0 0 0 8
1 0 0 1 001 1 0 0 0 3
1 1 0 0 320 0 1 0 0 6
1 2 4 1 212 4 0 1 0 15
1 3 2 0 201 0 0 0 1 6
1 6 0 1 000 0 0 0 0 1
T o t a l 1 5 1 0 2 0 8 1 2 1 03118 0
doi:10.1371/journal.pone.0032996.t001
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Agilent 2100 Bioanalyzer (Agilent Technologies, Foster City, CA
USA). RNA purity was assessed by the ratio of spectrophotometric
absorbance at 260 and 280 nm (A260/280 nm) using NanoDrop
ND-1000 (NanoDrop Inc, Wilmington, DE USA). All chips were
prepared according to the manufacturer’s instructions. Total RNA
degradation was evaluated by reviewing the electropherograms
and the RNA integrity number (RIN): only samples with preserved
18S and 28S peaks and RIN values greater than 7 were selected
for gene expression analysis. One microgram of RNA was used as
a template for DNA preparations and hybridized to Agilent
4644 K whole human genome arrays (Agilent Technologies).
cDNA was labeled with Cy5-dUTP and a reference control
(Stratagene) was labeled with Cy3-dUTP using the Agilent
(Agilent Technologies) low RNA input linear amplification kit
and hybridized overnight at 65uC to Agilent 4644 K whole
human genome arrays (Agilent Technologies). Arrays were washed
and scanned using an Agilent scanner (Agilent Technologies). All
data is MIAME compliant and the raw data is publicly available in
MIAME compliant Gene Expression Omnibus database (acces-
sion number: GSE21501).
Tissue Microarray
The tissue microarrays (TMAs) are made from paraffin blocks
of formalin fixed tissue from rapid autopsies. Large 2.0 and/or
2.5 mm cores are used to construct the tissue arrays. In addition to
the tumor cores, each block contains control specimens of
uninvolved kidney and colon tissue as well as pancreas from
non-cancerous donors. Once completed, the tissue microarray
blocks are cut into 4 micron thick sections and mounted on
charged slides.
Immunohistochemistry
Immunohistochemistry was performed by utilizing goat anti-
rabbit IgG-AP with Fast-Red to produce red stain (PicTure
TM-
Double Staining kit, Invitrogen), as per the manufacturer’s
instructions. Following primary antibodies were utilized: GLUT1
(Abcam, ab15309), HK2 (Cell Signaling Technology, 2867),
Aldolase B (Genway, 20-203-421205), b-Enolase (Aviva Systems
Biology, ARP48203_T10), PKM2 (Cell Signaling Technology,
3198), IDH3A (Abcam, ab58641). The intensity score was given
by evaluating staining intensity of positive staining (0=none;
1=+weak; 2=++ intermediate, 3=+++ strong). The proportion
score representing the percentage of positively stained cell
(0=none; 1=,5%; 2=5–25%; 3=26–50% 4=51–75%
5=.75%). The overall protein expression in each sample is
expressed as histoscore, which is the multiplication product of the
proportion (0–5) and intensity scores (0–3) and is between 0–15,
with a maximum of 15. The histoscore was calculated for the
tumor cells and stromal cells separately. The staining score was
evaluated by two independent observers and validated by a clinical
pathologist.
Statistical analysis
a. Microarray expression data. The two color Agilent
arrays were used to quantify the relative gene expressions from the
samples from either metastasis sites or primary cancer sites (labeled
by red channel) and the reference human mRNA samples
(Stratagene; labeled by green channel). The microarray
expression data were analyzed to identify differentially expressed
metabolic genes associated with certain metastasis site or primary
pancreatic cancer. First all array data were preprocessed by
filtering the data to eliminate poor quality spots or genes that did
not have mean intensity greater than 10 for one of the two
channels (green and red) in at least 70% of the experiments. The
filtered data were normalized using the Lowess normalization.
The log2 ratios between the intensity from red channel and green
channel were calculated, and the ratios with at least 30 for the
normalized raw intensity from both channels were included for
further analysis. The analysis was conducted on 74 metabolic
genes including 38 glycolytic genes, 25 TCA cycle genes, and 11
pentose phosphate pathway (PPP) associated genes (Table S1).
The genes/enzymes involved in glucose metabolism were searched
in Pubmed under ‘gene’ category (www.ncbi.nlm.nih.gov/gene)
for all the potential isoforms of a given enzyme regulating the
pathway. We noticed that a few genes were sampled more than
once on the same array. The data from the same gene on the same
array was then aggregated by taking an average. A mixed effect
model involving fixed effect from the primary pancreatic cancer or
metastasis site and random effect from subject was fit to each gene
to account for the correlation among the samples from the same
subject. The fixed effect from the primary pancreatic cancer or
metastasis sites measures the difference in the log-scale expression
between the primary cancer or metastasis and the reference
mRNA samples. Estimates for the fixed effect and the p-value
testing whether the fixed effect is equal to zero were calculated.
Following that, the BH (Benjamini Hochberg) method [16] was
used to control the false discovery rate (FDR) for multiple
comparisons on all the selected metabolic genes. A gene was
claimed to be differentially expressed only if the BH adjusted p-
value is smaller than 0.05. Heatmaps were drawn on all 74
metabolic genes for relative mRNA levels for each site in each
patient sample by utilizing the Genesis software [17]. The
heatmap displayed the mean log2 fold change of the gene
intensity between the samples from the metastasis site or the
primary pancreatic cancer site and the reference mRNA samples
in each patient. There are 8–20 samples per site. As we used the
Agilent array, the Agilent Feature Processing for the experiments
reported in this paper used the Feature Extraction Version 7.5.1
default settings recommended by Agilent. The SpotAnalyzer and
the PolyOutlierFlagger algorithms define the feature areas and flag
outliers. Spots are flagged and removed if pixel variation is too
high or if the spot intensity is found to be an outlier. The genes
were claimed to be differentially expressed for a certain metastasis
site or for the primary pancreatic cancer site if p,0.05.
b. Tissue microarray data. The overall gene expression in
each sample was quantified by a histoscore, which equals the
product of the proportion score (at a scale of 0–5, representing the
percentage of positively stained cell) and the intensity scores (at a
scale of 0–3, evaluating staining intensity of positive staining).
Median histoscore was reported for the stromal cells and tumor
from different metastatic or pancreatic tumor sections on each
gene. The histoscore values were compared between stromal cells
and tumor cells from the same metastatic or pancreatic tumor
Figure 1. mRNA expression profiles of metabolic genes in primary and metastatic lesions. The mRNA expression profiles from pancreatic
cancer patients were analyzed on 80 Agilent human whole genome 4644 K DNA microarrays. The heatmap was created by Genesis [17]. The
heatmap display the mean log2 fold change of the gene intensity between the samples from the metastasis site or the primary pancreatic cancer site
and the reference mRNA samples. The genes examined were functionally involved in glycolysis (A), Krebs tricarboxylic acid cycle (B) or pentose
phosphate pathways (C).
doi:10.1371/journal.pone.0032996.g001
Metabolic Gene Expression in Pancreatic Cancer
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The Friedman’s test was conducted on each gene to compare the
histoscores between stromal cells and tumor cells after adjusting
the site effects from different metastatic or tumor section.
Results
mRNA expression profile of glycolytic genes
We evaluated primary and metastatic tumor lesions for
alterations in metabolic gene expression signatures as compared
to normal tissue by gene expression array analyses of RNA
extracted from primary as well as metastatic tumor samples from
pancreatic cancer patient autopsies (Table S1). Heatmap of
glycolytic gene expression patterns in primary tumor or metastatic
lesions relative to standard reference tissue are shown in Figure 1A.
While we did not achieve stastistical significance for any genes in
the primary pancreatic tumors and lung metastatic lesions,
SLC2A1 (GLUT1) demonstrated robust overexpression in most
other metastatic lesions (less than 0.05 FDR corrected p values and
over 2 fold changes; Table S1). Similarly, PKM2 demonstrated
modest but significant overexpression in most other metastatic
lesions. HK2 was also overexpressed in fat and liver metastatic
tumors. ENO3 was overexpressed in the liver and muscle
metastasis sites. Liver and muscle metastatic lesions demonstrated
significant upregulation of the highest number of glycolytic genes.
A number of genes were expressed in a metastasis-site specific
manner. SLC2A2 (GLUT2) and ALDOB were overexpressed in
liver metastases, but had negative fold changes in the metastases at
most of the other sites. SLC2A4 (GLUT4), PFKM and PGAM2
were highly expressed only in the muscle metastatic lesions
compared to the reference mRNA.
mRNA expression profiles of TCA cycle genes
Alterations in the expression of TCA cycle regulating genes
were significant in liver or muscle metastasis sites. PC, ACO1,
IDH2 and PCK1 and were overexpressed in tumor samples from
liver metastases only (Figure 1B, Table S1). PC and PCK1 were
the most upregulated (over 5-fold) genes in liver metastases.
Several genes including CS, FH, ACO2, SUCLG1, SUCLA2,
IDH3A, IDH3B, MDH1, PDHA1, and QPs3 were overexpressed
only in muscle metastatic lesions. DLAT, and MDH2 were
overexpressed in both liver and muscle metastatic lesions. While
PCK2 was overexpressed in liver metastatic lesions, it was down-
regulated in muscle metastases. Overall, most of the TCA cycle
genes were upregulated in muscle metastatic lesions, indicating the
role played by TCA cycle in metastatic colonization or tumor
growth at the metastatic foci in skeletal muscles. We did not
observe any enrichment of mRNA levels of TCA cycle associated
genes in the primary pancreatic tumors. Most of the TCA cycle
genes had negative fold changes in lymph node metastatic lesions,
but the changes were not significant (FDR corrected p
value.0.05).
mRNA expression profiles of pentose phosphate
pathway (PPP) associated genes
Most genes involved in the pentose phosphate pathway
demonstrated only modest alterations in expression levels.
However, ribulose-5-phosphate epimerase (RPE) demonstrated
upregulation in fat and muscle metastasis sites (Figure 1C, Table
S1). PGLS and TKT were downregulated in muscle metastases.
PRPS1L1 and RPE were upregulated in muscle metastatic lesions,
while RBKS was upregulated in liver. Glucose-6-phosphate
dehydrogenase (G6PD), which catalyzes the first and the rate-
limiting step in PPP, did not demonstrate significant alterations at
mRNA levels.
Immunohistochemical staining of differentially expressed
genes
To confirm that alterations in the mRNA expression profiles of
the metabolic genes were reflected in protein expression, we
performed IHC staining for 7 metabolic genes on tissue
microarrays representing uninvolved pancreas (normal), pancre-
atic tumor, and metastatic lesions from liver, lung, lymph nodes,
and diaphragm. The metabolic genes selected were related to
glucose uptake (SLC2A1 or GLUT1), glycolysis (HK2, ALDOB,
ENO3, and PKM2), lactate production (LDHA) and TCA cycle
(IDH3A). The genes were chosen to evaluate some robustly
expressed genes from the microarray data sets (GLUT1, HK2);
some modestly but consistently overexpressed gene (PKM2) and
some genes overexpressed in a tissue specific manner (ALDOB
and ENO3 for Muscle and liver, and LDHA for liver).
Representative IHC images are illustrated in Figure 2. The
images depicting the expression of each gene at multiple sites
represent expression profiles in tissue samples from one
pancreatic cancer patient. Hence, they may not be in perfect
agreement with the median histoscore but still represent the
inherent variability in expression. We observed minimal to no
staining for these gene products in normal or uninvolved
pancreas. All tissue sections were scored for expression in tumor
and stroma. GLUT1 and HK2 were robustly expressed in most
primary tumors and metastatic lesions. ENO3 and LDHA were
moderately expressed. ALDOB expression levels were minimal in
most tissues. IDH3A and PKM2 were significantly expressed in
liver metastatic lesions.
Figure 3 presents the staining intensity scores for all the
proteins in each specimen for tumor, as well as, stromal cells.
Differential expression of proteins was observed between stromal
and tumor cells for ENO3, GLUT1, HK2, IDH3A, LDHA and
PKM2 (Table 2, Figure 4). However, the expression levels of
ALDOB were not significantly different between stromal and
tumor cells.
Comparing the expression levels between the tissue sections
from multiple patients, all pancreatic tumor specimens stained
positive for GLUT1, HK2, ENO3, LDHA and PKM2. All liver
metastatic lesions had positive stain intensities for GLUT1 and
ENO3. All lung metastatic lesions had positive stain intensities for
ENO3, PKM2, LDHA and IDH3A. All lymph node metastatic
lesions had positive stain intensities for GLUT1, HK2, PKM2 and
LDHA. All the diaphragm metastatic lesions had positive stain
intensities for GLUT1, HK2, IDH3A, PKM2 and LDHA. In
summary, GLUT1 was significantly expressed by all primary
tumor and metastatic lesion specimens of pancreatic cancer,
except lung metastatic lesions, and hence may serve as a good
marker for pancreatic cancer overall. Moreover, staining for
GLUT1 provided an median staining intensity score of 2 or above
in all the primary and metastatic lesions (Figure 4), GLUT1 and
Figure 2. Metabolic protein expression in primary and metastatic lesions of pancreatic adenocarcinomas. Immunohistochemical
examination of GLUT1 (A) HK2 (B), ALDOB (C), ENO3 (D), PKM2 (E), LDHA (F) IDH3A (G) expression in uninvolved pancreas, pancreatic tumor, and liver,
lung, lymph node and diaphragm metastatic lesions. The staining was performed with Fast-Red stain. The images were captured at 2006
magnification. Tumor cell area (T), stromal cell area (S) and uninvolved region (U) are indicated in the IHC images.
doi:10.1371/journal.pone.0032996.g002
Metabolic Gene Expression in Pancreatic Cancer
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metastatic lesions. Furthermore, stromal cells from all pancreatic
tumor sections and diaphragm metastatic legions stained positive
for GLUT1. Stromal cells from all the pancreatic tumor,
diaphragm and lung metastatic legions also stained positive for
PKM2.
Discussion
Pancreatic cancer displays alterations in cellular metabolism,
which affects disease progression and represents a significant target
to improve management of this disease [18,19]. Several oncogenes
and tumor suppressors have been implicated in altering tumor cell
Figure 3. Semiquantitative evaulation of protein expression levels based on immunohistochemical findings. Tumor cell (left) and
stromal(right)expressionlevelsofGLUT1,HK2,ALDOB,ENO3,PKM2,LDHAandIDH3Ainpancreatictumor(A),andliver(B),lung(C),lymphnode(D) and
diaphragm (E) metastatic lesions were graded on a scale of 0–3. The staining intensities are tabularized and indicated with gradations of red color.
doi:10.1371/journal.pone.0032996.g003
Metabolic Gene Expression in Pancreatic Cancer
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[20,21,22]. Such alterations facilitate production of an abundant
supply of key metabolic intermediates, which serve as essential
ingredients for biosynthetic processes to sustain cell proliferation.
The manner by which such alterations are involved in the
progression of pancreatic cancer and if they differ between
primary tumor and metastatic lesions at distant sites remain poorly
understood. The studies presented here are the first to evaluate
global metabolic alterations associated with metastasis to distant
sites. We also evaluated the relative expression profiles of
metabolic gene products between the tumor cells and the stromal
cells to understand the nature of interactions in metabolic
pathways between the tumor and stromal components of
pancreatic adenocarcinomas.
Our studies confirm that the metabolic nature of pancreatic
tumors is distinct from the normal pancreas. Most of the enzymes
linked with aerobic glycolysis are expressed at low levels in the
uninvolved pancreas, while they are significantly overexpressed in
the primary tumors, as well as the metastatic lesions. However, we
did not observe any significant changes in the expression of Krebs
cycle pathway enzymes between the uninvolved pancreatic and
tumor lesions. Although protein expression levels do not always
correlate with the enzyme activities, expression levels of glucose
transporters and metabolic enzymes have been correlated with
higher flux of glucose through glycolytic pathways in pancreatic
cancer [7,15]. Hence, the increased expression of glycolytic
machinery components suggests that pancreatic tumors might be
more dependent on aerobic glycolysis as compared to the
uninvolved pancreas.
We found that several genes associated with glucose uptake and
glycolysis are upregulated in primary as well as metastatic tumors.
GLUT1 is most abundantly overexpressed in primary as well as
metastatic tumors. Consistent with the Warburg’s hypothesis, we
found that tumor cells demonstrate significant upregulation of
glycolysis suggesting that most of the glucose that passes through
the glycolytic pathway is eventually converted into lactate and
secreted outside the tumor cells [2]. Since such a flux of glucose
skips the entry of metabolites into TCA cycle, the energy
production is significantly reduced [1]. To compensate for the
growing need of energy and sustain the supply of metabolites for
biosynthetic purposes, cells must allow for more glucose to be
processed per unit time. Hence, upregulation of GLUT1
represents one such mechanism whereby increased entry of
glucose ensures rapid proliferation and sustenance of biological
processes critical for proliferation, metastasis, and adaptation and
proliferation at the metastatic site [23]. Another enzyme, HKII,
was significantly upregulated at primary as well as metastatic loci.
Although the expression levels of HKII are not as prominently
increased as GLUT1, this could be explained by the fact that
HKII has a very low Km (0.1 mM); thus, it mostly functions at or
near its maximal rate under physiological conditions [24]. Hence,
even small increases in the levels of HKII will have significant
impact on the overall levels of glucose turnover.
The metabolic gene expression profiles of distant metastases are
predicted to be influenced by the cellular and stromal nature of the
sites of metastases, which are distinct from that of the primary
tumors. For example, IDH3A gene is underexpressed in liver
compared to metastases in diaphragm, and expression levels in
lungs and lymph nodes were even higher. IDH3A codes for the
mitochondrial NAD
+-specific isocitrate dehydrogenase a subunit,
which can generate citrate, indirectly from pyruvate or glutamine,
that can be converted by ACYL to Acetyl CoA, eventually
contributing to membrane synthesis, by ACC and FAS catalyzed
reactions. Although most of the glycolytic genes are significantly
overexpressed in primary as well as metastatic tumors, the
expression of enzymes that generate metabolites to feed into the
biosynthetic pathways may be differentially altered between
primary and metastatic sites. Overall, glycolytic genes show much
higher variations in the expression levels than the genes involved
in TCA cycle or PPP.
Our studies also demonstrate for the first time that the
expression of glycolytic genes is significantly higher in the tumor
cells than in the stromal cells of primary and metastatic pancreatic
tumors. In fact, genes such as GLUT1 and HKII are upregulated
over two-fold in the tumor cells as compared to the stromal cells.
This supports the hypothesis that tumor cells preferentially
consume glucose to generate lactate under aerobic conditions
(aerobic glycolysis). The secreted lactate may serve as an energy
source for stromal cells, which exhibit lower levels of glycolysis but
more functional activity in the Krebs cycle. Lactate, which can
reversibly be converted to pyruvate by pyruvate dehydrogenase,
can then enter the Krebs cycle in the mitochondria to provide
Table 2. Overall histoscore comparisons between the tumor
and stromal cells.
Gene Tumor
a Stromal
a p value
b
GLUT1 15 4 1.72E-08
HK2 10 1 3.97E-14
ALDOB 0 0 0.560141
ENO3 4 1 1.11E-05
PKM2 10 6 0.000371
LDHA 10 5 0.001534
IDH3A 10 5 0.000913
aMedian histoscores are presented for tumor and stromal cells.
bp value was calculated by Friedman’s test on histoscore values.
doi:10.1371/journal.pone.0032996.t002
Figure 4. Differential protein expression levels by immunohistochemistry. Average tumor cell versus stromal cell expression intensities of
GLUT1, HK2, ALDOB, ENO3, PKM2, LDHA and IDH3A in pancreatic tumor, and liver, lung, lymph node and diaphragm metastatic lesions are
tabularized and indicated with gradations of red color.
doi:10.1371/journal.pone.0032996.g004
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to establish such metabolic relationships between tumor and
stromal cells.
These studies also present GLUT1 as an overall metabolic
marker for the pancreatic cancer cells, whereas, IDH3A may serve
as an overall marker for the lung metastatic lesions of pancreatic
adenocarcinoma. Identification of such markers might be
significant in profiling the circulating tumor cells and predicting
the patterns of metastasis in patients. Whether such expression
patterns precede metastasis or are caused by the tumor
microenvironment at the site of colonization, remains to be
established.
Our studies compare metabolic gene expression both at the
level of mRNA as well as protein. Several studies indicate that
mRNA expression levels do not necessarily match with the protein
levels in cancer [25]. At mRNA level, we did not observe any
statistically significant changes for any genes in primary tumors
and lung metastatic lesions as compared to the reference tissue.
SLC2A1 (GLUT1) and PKM2 were the only genes that were
significantly overexpressed at all the remaining sites (Table S1).
However, at protein levels GLUT1, HK2, ENO3, PKM2, LDHA
and IDH3 were all significantly overexpressed in contrast to
normal pancreas. Our studies indicate that for primary and
metastatic sites some gene expression profiles match at mRNA
levels as well as protein level, while others demonstrate a
discordant relationship. For example, GLUT1 and PKM2 have
high expression levels at most sites in both mRNA and protein
levels. HK2 demonstrates similar but less robust expression at
mRNA level, while still significantly expressed at the protein level.
LDHA demonstrate significant overexpression only for liver
metastatic lesions at mRNA level, while it is significantly
overexpressed at most sites at the protein level (Table S1). The
discordant relationships indicate that the mRNA and protein levels
may not be directly linked for most metabolic genes. Limited
sample size for mRNA studies may be a factor for the modest
changes observed. However, we believe that our studies will
provide a scaffold for researchers investigating either mRNA or
protein expression changes and correlating such alterations with
diagnosis, progression and prognosis.
Very few studies exist that compare gene expression profiles for
primary tumors as well as multiple metastatic lesions. Although not
exactly comparable for the relative expression profiles as
performed in our studies, we reanalyzed our mRNA expression
profiles for primary tumors versus liver metastatic lesions in an
attempt to validate our findings with an external dataset
(GSE12630; Table S2). The comparison revealed that ALDOB,
SLC2A2, PC and PCK1 mRNA levels were significantly higher in
the liver metastatic lesions in comparison to the primary
pancreatic tumors. According to our IHC results and published
literature, expression levels of ALDOB, PC and PCK1, the latter
two being gluconeogenic enzymes, tend to be higher in normal
liver, a possible contaminant in the metastatic tissues utilized for
RNA preparation and microarray [26]. However, the expression
levels of SLC2A2 [27] tend to be significantly higher in tumor cells
in contrast to the normal tissue. Hence, SLC2A2 was seemingly
the only gene that was expressed significantly higher in liver
metastatic lesions in comparison to the primary pancreatic tumors,
in both the datasets.
The observed alterations in the expression of metabolic genes
are predicted to result from modulations in oncogenic and tumor
suppressor activities by the tumor cells. Pancreatic cancer cells
carry activating mutations in several oncogenes and inactivating
mutations in tumor suppressor. As 97% pancreatic cancer cells
carry activating mutations in Kras, and at least 50% have mutated
p53 tumor suppressor, it is predicted that such mutations and
commensurate oncogenic events contribute to overexpression of
the glycolytic genes. How such events lead to differential metabolic
expression profiles in primary vs. metastatic lesions will be
determined by future studies. Overall, our studies provide support
for the concept that metabolism contributes to the aggressive
nature of pancreatic tumors and their early metastases. Further
studies will lead to development of metabolism-based biomarkers/
therapeutics for the diagnosis/treatment of pancreatic cancer
metastasis.
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